Clinical Trial Update: Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cobimetinib in newly diagnosed or HMA-treated CMML patients with RAS pathway mutations has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelomonocytic Leukemia

Drugs mentioned

• Cobimetinib (cobimetinib)

Snippet

Sponsor: University of Utah | Conditions: Chronic Myelomonocytic Leukemia (CMML) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-24